The Gross Margin of REGENXBIO Inc. (RGNX) is
88.09%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2025-12-31 |
88.09%
|
| 2024-12-31 |
59.72%
|
| 2023-12-31 |
58.76%
|
| 2022-12-31 |
51.64%
|
| 2021-12-31 |
88.99%
|
| 2020-12-31 |
76.91%
|
| 2019-12-31 |
76.70%
|
| 2018-12-31 |
95.61%
|
| 2017-12-31 |
83.65%
|
| 2016-12-31 |
78.26%
|
| Ticker |
Name |
Value |
|
ABBV
|
AbbVie Inc.
|
71.62%
|
|
MRNA
|
Moderna, Inc.
|
70.32%
|
|
NKTX
|
Nkarta, Inc.
|
7775.20%
|
|
REPL
|
Replimune Group, Inc.
|
7775.20%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
13.28%
|
|
950200.KQ
|
Psomagen Inc
|
24.48%
|
|
CCCC
|
C4 Therapeutics, Inc.
|
7775.20%
|
|
KROS
|
Keros Therapeutics, Inc.
|
7775.20%
|
|
STTK
|
Shattuck Labs Inc
|
7775.20%
|
|
950220.KQ
|
Neoimmunetech Inc
|
7775.20%
|
|
BLUE
|
Genetix Biotherapeutics Inc
|
-6.65%
|
|
MCRB
|
Seres Therapeutics, Inc.
|
7775.20%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
86.56%
|
|
YMAB
|
Y-mAbs Therapeutics Inc
|
82.89%
|
|
GILD
|
Gilead Sciences, Inc.
|
78.84%
|
|
IMVT
|
Immunovant, Inc.
|
7775.20%
|
|
DVAX
|
Dynavax Technologies Corp
|
82.17%
|
|
KNTE
|
Kinnate Biopharma Inc
|
7775.20%
|
|
QURE
|
uniQure N.V.
|
89.53%
|
|
ARQT
|
Arcutis Biotherapeutics, Inc.
|
90.24%
|
|
CYTK
|
Cytokinetics, Incorporated
|
7775.20%
|
|
IMGN
|
ImmunoGen Inc
|
99.82%
|
|
KRON
|
Kronos Bio LLC
|
7775.20%
|
|
VBIV
|
VBI Vaccines Inc
|
-44.06%
|
|
DMTK
|
DermTech Inc
|
1.80%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
86.24%
|
|
KRYS
|
Krystal Biotech, Inc.
|
94.08%
|
|
OCGN
|
Ocugen, Inc.
|
7775.20%
|
|
SGMO
|
Sangamo Therapeutics Inc
|
7775.20%
|
|
NRIX
|
Nurix Therapeutics, Inc.
|
7775.20%
|
|
ZYME
|
Zymeworks Inc.
|
7775.20%
|
|
ALEC
|
Alector, Inc.
|
7775.20%
|
|
AMGN
|
Amgen Inc
|
70.78%
|